Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bluejeans who wrote (21521)	5/28/1998 5:52:00 PM
From: Machaon	Read Replies (3) \| Respond to of 32384

From today's news release: << "In addition, Ligand's submission of this NDA suggests the promise held for use of 9-cis retinoic acid for treatment of other diseases," said Ronald M. Evans, Ph.D., Ligand scientific founder, professor in the Gene Expression Laboratory at The Salk Institute and a Howard Hughes Medical Institute investigator.>> I think that Ligand went after KS, because it was a skin cancer where it was possible to get a good base of people enrolled. It would've been very difficult to enroll patients, for other types of skin cancers, because there is a current method of dealing with most skin cancers- Surgery. Most people with skin cancer want to have the cancer removed, and don't want to take the chance of experimental drugs. Patients with AIDS related KS don't have much choice. So, those who ask why LGND chose to attack AIDS related KS, a relatively small market, might consider the options that Ligand had to deal with. Now that Panretin Gel has been shown effective against skin cancer, of the KS type, it opens up a possibly huge market for other types of skin cancer, upon FDA approval of Panretin for KS. Anyway, makes sense to me. Any other takes? Good luck, Bob